Eikon Therapeutics Inc.

02/09/2026 | Press release | Distributed by Public on 02/09/2026 20:19

Statement of Changes in Beneficial Ownership (Form 4)

FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden hours per response... 0.5
(Print or Type Responses)
1. Name and Address of Reporting Person *
Column Group IV GP, LP
2. Issuer Name and Ticker or Trading Symbol
Eikon Therapeutics, Inc. [EIKN]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director __X__ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
(Last) (First) (Middle)
1 LETTERMAN DR., BLDG D, SUITE DM-900
3. Date of Earliest Transaction (Month/Day/Year)
02/06/2026
(Street)
SAN FRANCISCO, CA 94129
4. If Amendment, Date Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/06/2026 C(1) 1,296,629 A (1) 1,360,320 I By The Column Group IV, LP(2)
Common Stock 02/06/2026 C(1) 1,403,568 A (1) 2,763,888 I By The Column Group IV, LP(2)
Common Stock 02/06/2026 C(1) 110,928 A (1) 2,874,816 I By The Column Group IV, LP(2)
Common Stock 02/06/2026 C(1) 44,249 A (1) 47,601 I By The Column Group IV-A, LP(3)
Common Stock 02/06/2026 C(1) 47,898 A (1) 95,499 I By The Column Group IV-A, LP(3)
Common Stock 02/06/2026 C(1) 3,785 A (1) 99,284 I By The Column Group IV-A, LP(3)
Common Stock 02/06/2026 C(1) 688,283 A (1) 688,283 I By The Column Group Opportunity III, LP(4)
Common Stock 02/06/2026 P 1,437,323 A $18 4,312,139 I By The Column Group IV, LP(2)
Common Stock 02/06/2026 P 49,556 A $18 148,840 I By The Column Group IV-A, LP(3)
Common Stock 02/06/2026 P 630,881 A $18 1,319,164 I By The Column Group Opportunity III, LP(4)
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(Month/Day/Year)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Series A Preferred Stock (1) 02/06/2026 C(1) 9,670,000 (1) (1) Common Stock 1,296,629 (1) 0 I By The Column Group IV, LP(2)
Series A Preferred Stock (1) 02/06/2026 C(1) 330,000 (1) (1) Common Stock 44,249 (1) 0 I By The Column Group IV-A, LP(3)
Series A-1 Preferred Stock (1) 02/06/2026 C(1) 10,467,526 (1) (1) Common Stock 1,403,568 (1) 0 I By The Column Group IV, LP(2)
Series A-1 Preferred Stock (1) 02/06/2026 C(1) 357,216 (1) (1) Common Stock 47,898 (1) 0 I By The Column Group IV-A, LP(3)
Series C-1 Preferred Stock (1) 02/06/2026 C(1) 827,278 (1) (1) Common Stock 110,928 (1) 0 I By The Column Group IV, LP(2)
Series C-1 Preferred Stock (1) 02/06/2026 C(1) 28,229 (1) (1) Common Stock 3,785 (1) 0 I By The Column Group IV-A, LP(3)
Series D Preferred Stock (1) 02/06/2026 C(1) 5,133,076 (1) (1) Common Stock 688,283 (1) 0 I By The Column Group Opportunity III, LP(4)

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Column Group IV GP, LP
1 LETTERMAN DR., BLDG D, SUITE DM-900
SAN FRANCISCO, CA 94129
X
Column Group IV-A, LP
1 LETTERMAN DR., BLDG D, SUITE DM-900
SAN FRANCISCO, CA 94129
X
Column Group IV, LP
1 LETTERMAN DR., BLDG D, SUITE DM-900
SAN FRANCISCO, CA 94129
X
Column Group Opportunity III, LP
1 LETTERMAN DR., BLDG D, SUITE DM-900
SAN FRANCISCO, CA 94129
X
Column Group Opportunity III GP, LP
1 LETTERMAN DR., BLDG D, SUITE DM-900
SAN FRANCISCO, CA 94129
X
TCG Opportunity III GP, LLC
1 LETTERMAN DR., BLDG D, SUITE DM-900
SAN FRANCISCO, CA 94129
X
Kutzkey Tim
1 LETTERMAN DR., BLDG D, SUITE DM-900
SAN FRANCISCO, CA 94129
X
Svennilson Peter
1 LETTERMAN DR., BLDG D, SUITE DM-900
SAN FRANCISCO, CA 94129
X

Signatures

/s/ The Column Group IV GP, LP, /s/ James Evangelista, Attorney-in-Fact 02/09/2026
**Signature of Reporting Person Date
/s/ The Column Group IV-A, LP. by The Column Group IV GP, LP, its general partner, /s/ James Evangelista, Attorney-in-Fact 02/09/2026
**Signature of Reporting Person Date
/s/ The Column Group IV, LP by The Column Group IV GP, LP, its general partner /s/ James Evangelista, Attorney-in-Fact 02/09/2026
**Signature of Reporting Person Date
/s/ The Column Group Opportunity III, LP, by The Column Group Opportunity GP, LP its general partner, by TCG Opportunity III GP, LLC, its general partner, /s/ James Evangelista, Attorney-in-Fact 02/09/2026
**Signature of Reporting Person Date
/s/ The Column Group Opportunity III GP, LP., by TCG Opportunity III GP, LLC, its general partner, /s/ James Evangelista, Attorney-in-Fact 02/09/2026
**Signature of Reporting Person Date
/s/ TCG Opportunity III GP, LLC, /s/ James Evangelista, Attorney-in-Fact 02/09/2026
**Signature of Reporting Person Date
/s/James Evangelista, as attorney-in-fact for Tim Kutzkey 02/09/2026
**Signature of Reporting Person Date
/s/James Evangelista, as attorney-in-fact for Peter Svennilson 02/09/2026
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date
(2) The shares are directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to shares directly held by TCG IV LP. Peter Svennilson and Tim Kutzkey are the managing partners of TCG IV GP LP and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG IV LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein.
(3) The shares are directly held by The Column Group IV-A, LP ("TCG IV-A LP"). TCG IV GP LP is the general partner of the TCG IV-A LP and may be deemed to have voting and investment power with respect to shares directly held by the Reporting Person. Peter Svennilson and Tim Kutzkey are the managing partners of TCG IV GP LP and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG IV-A LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein.
(4) The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP. TCG Opportunity III GP, LLC is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP. Each of TCG Opportunity III GP LP and TCG Opportunity III GP, LLC may be deemed to have voting, investment and dispositive power with respect to securities directly held by TCG Opportunity III LP. Peter Svennilson and Tim Kutzkey are the managing members of TCG Opportunity III GP, LLC and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG Opportunity III LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein.
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.
Eikon Therapeutics Inc. published this content on February 09, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on February 10, 2026 at 02:19 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]